信立泰(002294.SZ)：阿利沙坦酯氨氯地平片(复立坦®)获得药品注册证书

智通财经05-21

智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的阿利沙坦酯氨氯地平片(复立坦®)药品注册证书。据悉，阿利沙坦酯氨氯地平片(复立坦®)用于治疗原发性高血压，适用于单用阿利沙坦酯或单用氨氯地平治疗血压控制效果不佳的成人患者，为国产原研ARB/CCB类复方制剂(项目代码：SAL0107)。其组分经典，可靠性高，降压疗效得到充分验证。该产品上市后，将有...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2437924954?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-21 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437924954","market":"sh","top_or_hot":-1,"title":"信立泰(002294.SZ)：阿利沙坦酯氨氯地平片(复立坦®)获得药品注册证书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的阿利沙坦酯氨氯地平片(复立坦®)药品注册证书。据悉，阿利沙坦酯氨氯地平片(复立坦®)用于治疗原发性高血压，适用于单用阿利沙坦酯或单用氨氯地平治疗血压控制效果不佳的成人患者，为国产原研ARB/CCB类复方制剂(项目代码：SAL0107)。其组分经典，可靠性高，降压疗效得到充分验证。该产品上市后，将有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1123945.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信立泰(002294.SZ)：阿利沙坦酯氨氯地平片(复立坦®)获得药品注册证书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信立泰(002294.SZ)：阿利沙坦酯氨氯地平片(复立坦®)获得药品注册证书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1123945.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的阿利沙坦酯氨氯地平片(复立坦®)药品注册证书。据悉，阿利沙坦酯氨氯地平片(复立坦®)用于治疗原发性高血压，适用于单用阿利沙坦酯或单用氨氯地平治疗血压控制效果不佳的成人患者，为国产原研ARB/CCB类复方制剂(项目代码：SAL0107)。其组分经典，可靠性高，降压疗效得到充分验证。该产品上市后，将有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1123945.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1123945.html","article_id":"2437924954","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437924954","pubTimestamp":1716285805,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，信立泰 发布公告，近日，公司收到国家药品监督管理局核准签发的阿利沙坦酯氨氯地平片(复立坦)药品注册证书。据悉，阿利沙坦酯氨氯地平片(复立坦)用于治疗原发性高血压，适用于单用阿利沙坦酯或单用氨氯地平治疗血压控制效果不佳的成人患者，为国产原研ARB/CCB类复方制剂。其组分经典，可靠性高，降压疗效得到充分验证。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0028":"国家队","BK0187":"一线龙头","BK0183":"MSCI概念","BK0188":"融资融券","BK0239":"医药制造","BK0196":"行业龙头","002294":"信立泰"},"translate_title":"Xinlitai (002294. SZ): Alisartan Medoxomilodipine Tablets (Fulitan ®) obtained the drug registration certificate","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002294":1},"content_text":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的阿利沙坦酯氨氯地平片(复立坦®)药品注册证书。据悉，阿利沙坦酯氨氯地平片(复立坦®)用于治疗原发性高血压，适用于单用阿利沙坦酯或单用氨氯地平治疗血压控制效果不佳的成人患者，为国产原研ARB/CCB类复方制剂(项目代码：SAL0107)。其组分经典，可靠性高，降压疗效得到充分验证。该产品上市后，将有针对性地覆盖不同细分领域的高血压者，满足未被满足的临床需求;同时与已上市的1类创新药ARB信立坦(阿利沙坦酯片)在多渠道、医院、科室、医生和患者等方面形成战略协同，进一步丰富公司高血压领域的创新产品管线，提升公司在心血管慢病领域的综合竞争力。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437924954"}